NSE: SOTAC · Healthcare · Pharmaceuticals · SME · Market cap ₹143 Cr
· Prev close ₹130.00 · Volume 1.20 K · 52W ₹86–140
Company profile · as of 20 Apr 2026
Sells Pharmaceuticals.
Net margin 9.6% (FY25)
Median of the other 3: 10.2%
Generated Return on capital is 14.3%, 2nd of 4 listed peers; Par Drugs And Chemicals is first at 17.5%.
Profit, last 4 quarters vs the 4 before: not in our data yet
Generated In FY25 revenue was −6.6% and net profit +159.2% on FY24.
P/E not shown: no EPS for four consecutive quarters or a recent year in our data
Peers' median 11.2×
Generated The P/E at the FY25 year-end was 16.3×; the other 3 listed peers have a median of 11.2×.
Of profit came in as cash, last 5 fiscal years: not in our data yet
100%: all profit arrived as cash
Generated Operating cash was negative in FY21, FY24 and FY25 and positive in the other two years; FY25 used ₹4 cr. Total debt was ₹44 cr at the end of FY25, against a net worth of ₹53 cr.
Domestic funds −0.68 pp last quarter · promoters 72.8%, unchanged
Generated Domestic funds held 0.00% at Sep 25, against 0.00% at Apr 23 and 0.68% at Mar 25. Foreign funds held 16.14% (12.88% at Apr 23); promoters held 72.8% in all 6 quarters.
In 1 month: not in our data yet
Generated The 52-week range runs from ₹86 to ₹139.65; the 12 Nov close of ₹129.35 sits 81% of the way up. Over 1 year it is up 0.3%, and the close is above its 20 and 50-day averages of ₹106 and ₹107.
An earnings call transcript: not in our data yet
Scored statements from the earnings calls: none yet.
Earnings outlook Generated
In Q4 FY26 (Mar 26), net profit was −45.7% on the year-earlier quarter; operating margin was 17.1%.
An earnings call transcript: not in our data yet